Effect of Vitamin D Supplementation on Bone Mineral Density in Rheumatoid Arthritis Patients With Osteoporosis

Oh Chan Kwon 1, Ji Seon Oh 2, Min-Chan Park 1* and Yong-Gil Kim 3*

1 Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 2 Department of Biomedical Informatics, Asan Medical Center, Seoul, South Korea, 3 Division of Rheumatology, Department of Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, South Korea

Objectives: To assess the effect of vitamin D supplementation on bone mineral density (BMD) in rheumatoid arthritis (RA) patients with osteoporosis and determine whether supplementation of more than 800 IU/day, which is the currently recommended dose, is beneficial.

Methods: RA patients with osteoporosis who received bisphosphonates were included. Patients were classified into four groups according to the dose of vitamin D supplementation (0, 400, 800, and ≥1,000 IU/day). Multivariable linear regression models were performed to evaluate the effect of each dose of vitamin D supplementation on 1-year % change of BMD.

Results: In total, 187 RA patients with osteoporosis were included. In the multivariate model adjusted for potential confounders, patients receiving vitamin D supplementation had a significantly higher increase in 1-year % change in lumbar spine BMD (400 IU/day: β = 2.51 [95% CI: 0.04–4.99], 800 IU/day: β = 2.90 [95% CI: 0.47–5.33], and ≥1,000 IU/day: β = 6.01 [95% CI: 3.71–9.32]) and femoral neck BMD (400 IU/day: β = 3.88 [95% CI: 1.83–5.94], 800 IU/day: β = 4.30 [95% CI: 2.25–6.35], and ≥1,000 IU/day: β = 6.79 [95% CI: 4.87–8.71]) than those not receiving the supplementation. Notably, the ≥1,000-IU/day group had a significantly higher increase in 1-year % change in lumbar spine BMD (β = 3.11 [95% CI: 0.86–5.37]) and femoral neck BMD (β = 2.50 [95% CI: 0.63–4.36]) than the 800-IU/day group.

Conclusion: In RA patients with osteoporosis receiving bisphosphonates, vitamin D supplementation was associated with a higher increase in BMD. This effect was higher in the vitamin D supplementation dose of ≥1,000 IU/day than in 800 IU/day.

Keywords: rheumatoid arthritis, osteoporosis, vitamin D, supplementation, bone mineral density

INTRODUCTION

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammatory arthritis (1). Since RA is a disease in which long-term glucocorticoid is commonly used (1), glucocorticoid-induced osteoporosis (GIOP) is an important comorbidity that needs to be considered when treating patients with RA. Indeed, population-based studies have reported a higher risk of osteoporosis in patients with RA (2, 3).
In the 2017 American College of Rheumatology guideline for the prevention and treatment of GIOP, a vitamin D intake of 600–800 IU/day has been recommended (4). Similarly, the Korean guideline for the prevention and treatment of GIOP also recommends a vitamin D intake of 800 IU/day (5). However, the recommended vitamin D intake of 600–800 IU/day is based on general population data, rather than those of patients with specific diseases, including RA, who require long-term glucocorticoid therapy (6). Due to the indirectness of the evidence, a vitamin D intake of 600–800 IU/day is only conditionally recommended in the GIOP guideline (4). Currently, data about the effect of vitamin D supplementation on bone mineral density (BMD) in RA patients with osteoporosis are limited, and the optimal dose of supplementation remains unclear.

Osteoporosis is characterized by low BMD and microarchitectural deterioration of the bone tissues, leading to an increased risk of fracture (7). Vitamin D affects the rate of bone turnover and the overall mineralization of the bone. Thus, vitamin D deficiency is associated with a higher bone turnover and incidence of fracture (8). Considering that vitamin D deficiency is highly prevalent in RA patients (9, 10), the required dose of vitamin D supplementation in RA patients with osteoporosis might be higher than the recommended intake of 600–800 IU/day (4), which is based on general population data.

This study aimed to assess the effect of vitamin D supplementation on BMD in RA patients with osteoporosis and to determine whether a dose higher than 800 IU/day is more effective in improving BMD in patients with RA.

PATIENTS AND METHODS

Study Population

Electronic medical records of RA patients who were newly diagnosed with osteoporosis and who started receiving bisphosphonates at two tertiary referral hospitals in Seoul, South Korea, between 2013 and 2017 were retrospectively reviewed. All patients met the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for RA (11). A diagnosis of osteoporosis was made based on the following BMD results: lumbar spine T-score ≤−2.5 and/or femoral neck T-score ≤−2.5. Patients who were taking medications other than bisphosphonates (selective estrogen receptor modulators, and teriparatide) for the treatment of osteoporosis, those with metabolic diseases, such as thyroid and parathyroid diseases, that can affect BMD, those with a history of previous fracture, and those who were current smokers were excluded.

This study was approved by the Institutional Review Board (IRB) of Gangnam Severance Hospital (IRB No: 3-2020-0043) and Asan Medical Center in Seoul, South Korea (IRB No: 2018-0090). Requirement of informed consent was waived because of the retrospective nature of the study.

BMD Assessment and Outcome Variables

BMDs of the lumbar spine (first to fourth vertebrae) and femoral neck were evaluated using dual-energy X-ray absorptiometry (GE Healthcare Lunar or Hologic system) (12). As per the insurance policy in our country, BMD was assessed annually (i.e., for insurance coverage, BMD data must be obtained every year). The same instrument was used for repeat BMD measurement in each patient. The BMD results of the Hologic system were converted to GE Healthcare Lunar BMD results using the conversion equation (13). Data about BMD results at the diagnosis of osteoporosis and after 1 year of treatment were collected for analysis. Outcome variables were 1-year % change in lumbar spine and femoral neck BMDs.

Vitamin D Supplementation

The average dietary intake of vitamin D is relatively low in South Korea (male: 160 IU/day, and female: 104 IU/day) (14), and as the majority of vitamin D intake comes from supplementation rather than diet, we focused on the dose of supplementation of vitamin D. Vitamin D supplements were in the form of calcium–vitamin D complex tablet or bisphosphonate–vitamin D complex tablet. Each tablet contained a specific amount of vitamin D [calcium–vitamin D complex for daily use: 400, 800, and 1,000 IU/tablet; bisphosphonate–vitamin D complex for weekly use: 5,600 IU/tablet [equivalent to 800 IU/day] (15); or bisphosphonate–vitamin D complex for monthly use: 24,000 IU/tablet [equivalent to 800 IU/day] (15)]. Thus, the vitamin D supplementation dose was used as a categorical variable rather than a continuous variable. The type of vitamin D supplement was chosen based on the treating physicians’ preference. Patients were classified into four groups according to the dosage of vitamin D supplementation, which were as follows: 0, 400, 800, and ≥1,000 IU/day. As calcium supplementation was provided in the form of calcium–vitamin D complex tablet, the 0-IU/day group also did not receive any calcium supplementation, whereas the other three groups received 500–1,000 mg/day of calcium supplementation in the form of calcium–vitamin D complex tablet. The average dietary intake of calcium in South Korea is 542 mg/day (16). Therefore, the total calcium intake (total of diet and supplementation) of patients receiving vitamin D supplementation was ≈1,000–1,500 mg/day, which was in accordance with the recommended calcium intake of 1,000–1,200 mg/day (4).

Covariates

At the time of diagnosis of osteoporosis, the following data were collected: age, sex, body mass index (BMI), positivity to rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody, and disease activity score 28 with erythrocyte sedimentation rate (DAS28-ESR). Data about medications prescribed during the 1-year interval between the BMD tests, including cumulative dose of glucocorticoid, use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and biologic DMARDs (bDMARDs), and type of bisphosphonate, were reviewed. For glucocorticoid use, the total glucocorticoid dose prior to the initial BMD test, and the current status (users or not) of glucocorticoid use at the initial BMD test were also reviewed.
Statistical Analysis
To compare the different groups, ANOVA was used for continuous variables and the chi-square test (when <20% of cells had expected count <5) or Fisher’s exact test (when 20% or more cells had expected count <5) was used for categorical variables. Multivariable linear regression analyses were performed to assess the effect of vitamin D supplementation on 1-year % changes in BMD. For each category of vitamin D supplementation dosage, we estimated the mean difference (effect estimate [β] and 95% confidence interval [CI]) in 1-year % changes in BMD between patients with and without vitamin D supplementation. Potential confounders, such as age, sex, BMI, total glucocorticoid dose prior to the initial BMD test, cumulative glucocorticoid dose between BMD measurements, use of csDMARDs and bDMARDs, DAS28-ESR, and type of bisphosphonate, were adjusted in the multivariable models using enter method. The variation inflation factor (VIF) was assessed to exclude multicollinearity among covariates included in the multivariable analyses. VIFs of all covariates were less than 5, confirming the absence of multicollinearity. The normality of the residual was tested using a histogram and normal P–P plot of the regression standardized residual, and the homoscedasticity of the residual was assessed using the scatter plot: the residual followed a normal distribution and was homoscedastic. Further, to evaluate whether a vitamin D supplementation dose of >800 IU/day is more effective than that of 800 IU/day in terms of improving BMD, the mean difference in 1-year % change in BMD between the ≥1,000- and 800-IU/day groups was assessed. P < 0.05 was considered statistically significant. All analyses were conducted using the SPSS software (version 25.0; IBM Corporation, Armonk, NY, USA).

RESULTS
Comparison Among the Different Vitamin D Supplementation Dose Groups
A total of 286 patients with RA, who were newly diagnosed with osteoporosis, were identified. Thirty-two patients who received medication other than bisphosphonate (selective estrogen receptor modulators: 30 patients, and teriparatide: 2 patients) for the treatment of osteoporosis, 14 patients with thyroid disease, 2 patients with parathyroid disease, 12 patients with a history of previous fracture, and 39 patients who were current smoker were excluded. The remaining 187 RA patients with osteoporosis were included in the analysis. Sixty-one patients did not receive vitamin D supplementation (0-IU/day group), whereas 23, 73, and 30 patients received vitamin D supplementation at a dose of 400 IU/day (400-IU/day group), 800 IU/day (800-IU/day group), and ≥1,000 IU/day (≥1,000-IU/day group), respectively. In the ≥1,000-IU/day group, 26 (86.7%) patients received 1,000 IU/day, one (3.3%) patient received 1,200 IU/day, and three (10.0%) patients received 1,800 IU/day. Comparison results among the different groups are shown in Table 1. The four groups did not differ in terms of age (p = 0.641), sex distribution (p = 0.570), BMI (p = 0.915), positivity to RF (p = 0.633) and anti-CCP antibody (p = 0.248), total glucocorticoid dose prior to the initial BMD test (p = 0.605), proportion of current glucocorticoid users (p = 0.109), cumulative dose of glucocorticoid between BMD tests (p = 0.246), use of csDMARDs (methotrexate, p = 0.416; hydroxychloroquine, p = 0.752; sulfasalazine, p = 0.731; leflunomide, p = 0.621; and tacrolimus, p = 0.946) and bDMARDs (tumor necrosis factor inhibitor, p = 0.134; tocilizumab, p = 0.610; and abatacept, p = 0.851), and DAS28-ESR (p = 0.846). The type of bisphosphonate used (risedronate: p < 0.001, alendronate: p < 0.001, and ibandronate: p = 0.001) was different among the groups (Table 1).

According to the initial BMD, 94 (50.3%) patients had osteoporosis in the lumbar spine, 33 (17.6%) patients had osteoporosis in the femoral neck, and 60 (32.1%) patients had osteoporosis in both lumbar spine and femoral neck. The initial lumbar spine T-score (p = 0.737) and initial femoral neck T-score (p = 0.252) did not differ among the four groups. The mean values of 1-year % changes in the lumbar spine BMD and femoral neck BMD in the total study population were 3.92 and 1.19%, respectively. The 1-year % change of lumbar spine BMD (p < 0.001) and femoral neck BMD (p < 0.001) was significantly different among groups (Table 1 and Figure 1).

Effect of Vitamin D Supplementation on 1-year % Changes in BMD
The results of linear regression analyses are shown in Table 2. The overall p value for the regression was p < 0.001 for all univariable and multivariable analyses. The total amount of variance explained in the univariable and in the multivariable analyses was as follows: univariable (lumbar spine), 0.210; multivariable (lumbar spine), 0.298; univariable (femoral neck), 0.281; and multivariable (femoral neck), 0.370. In the multivariable analysis, the 1-year % change in lumbar spine BMD was significantly higher in the vitamin D supplementation groups (400 IU/day: β = 2.51 [95% CI 0.04–4.99], p = 0.047; 800 IU/day: β = 2.90 [95% CI 0.47–5.33], p = 0.020; and ≥1,000 IU/day: β = 6.01 [95% CI 3.71–8.32], p < 0.001) than in the 0-IU/day group. Similarly, the supplementation of vitamin D, regardless of dose, was significantly associated with a higher 1-year % change in femoral neck BMD (400 IU/day: β = 3.38 [95% CI 1.83–5.94], p < 0.001; 800 IU/day: β = 4.30 [95% CI 2.25–6.35], p < 0.001; and ≥1,000 IU/day: β = 6.79 [95% CI 4.87–8.71], p < 0.001) (Table 2). Coefficients and their significance levels of all variables included in the multivariable analysis are shown in Supplementary Table 1.

Comparison of 1-year % Changes in BMD Between the ≥1,000- and 800-IU/day Groups
In the multivariable linear regression analysis comparing the effects of ≥1,000 and 800 IU/day, a vitamin D supplementation of ≥1,000 IU/day was associated with a significantly higher 1-year % change in lumbar spine BMD (β = 3.11 [95% CI 0.86–5.37], p = 0.007) and femoral neck BMD (β = 2.50 [95% CI 0.63–4.36], p = 0.009) (Table 3).
### DISCUSSION

In this retrospective study, we showed that in RA patients with osteoporosis who were receiving bisphosphonates, the supplementation of vitamin D was significantly associated with a higher increase in lumbar spine and femoral neck BMDs within 1 year. The mean differences in 1-year % changes in lumbar spine and femoral neck BMD were the highest in the ≥1,000 IU/day group. Notably, ≥1,000 IU/day of vitamin D supplementation was associated with a 3.11% (95% CI: 0.86–5.37%) and 2.50% (95% CI: 0.63–4.36%) higher increase in 1-year % changes in lumbar spine and femoral neck BMD, respectively, compared with 800 IU/day of vitamin D supplementation. This finding has an important clinical implication in that it indicates that a vitamin D supplementation dose higher than that recommended in the current GIOP guideline (4) might be beneficial in terms of improving BMD in RA patients with osteoporosis.

In previous studies evaluating the effect of vitamin D supplementation in non-osteoporotic participants, a 1-year % change in BMD was 1.0–2.5% higher in patients receiving vitamin D supplementation (400–800 IU/day) than in those

---

**TABLE 1 | Characteristics of patients (n = 187) according to the dose of vitamin D supplementation.**

| Characteristic | 0 IU/day (n = 61) | 400 IU/day (n = 23) | 800 IU/day (n = 73) | ≥1,000 IU/day (n = 30) | P |
|---------------|------------------|-------------------|-------------------|----------------------|---|
| **USE OF CSDMARDS, N (%)** | | | | | |
| MTX | 52 (85.2) | 19 (82.6) | 67 (91.8) | 25 (83.3) | 0.416 |
| HCQ | 28 (45.9) | 8 (34.8) | 30 (41.1) | 11 (36.7) | 0.752 |
| SSZ | 12 (19.7) | 7 (30.4) | 15 (20.5) | 6 (20.0) | 0.731 |
| LEF | 9 (14.8) | 5 (21.7) | 9 (12.3) | 3 (10.0) | 0.621 |
| TAC | 4 (6.6) | 2 (8.7) | 4 (5.5) | 2 (6.7) | 0.946 |
| **USE OF BDMARDS, N (%)** | | | | | |
| TNFi | 1 (1.6) | 0 (0.0) | 6 (8.2) | 3 (10.0) | 0.134 |
| Tocilizumab | 1 (1.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.610 |
| Abatacept | 2 (3.3) | 0 (0.0) | 1 (1.4) | 0 (0.0) | 0.851 |
| DAS28-ESR, mean ± SD | 3.19 ± 1.04 | 3.11 ± 0.71 | 3.19 ± 0.93 | 3.03 ± 0.73 | 0.846 |
| **BASELINE BMD, MEAN ± SD** | | | | | |
| Lumbar spine T-score | −2.93 ± 0.84 | −2.72 ± 1.23 | −2.85 ± 0.96 | −2.99 ± 0.95 | 0.737 |
| Femoral neck T-score | −2.41 ± 0.72 | −2.35 ± 0.85 | −2.17 ± 0.79 | −2.43 ± 0.71 | 0.252 |
| **BMD AT 1 YEAR, MEAN ± SD** | | | | | |
| Lumbar spine T-score | −2.85 ± 0.86 | −2.46 ± 1.26 | −2.52 ± 0.98 | −2.50 ± 0.99 | 0.161 |
| Femoral neck T-score | −2.44 ± 0.74 | −2.28 ± 0.80 | −2.11 ± 0.77 | −2.29 ± 0.67 | 0.093 |
| **1-YEAR % CHANGE, MEAN ± SD** | | | | | |
| Lumbar spine BMD | 0.71 ± 5.29 | 3.89 ± 4.13 | 5.17 ± 4.93 | 7.42 ± 3.64 | <0.001 |
| Femoral neck BMD | −2.09 ± 4.74 | 1.82 ± 3.64 | 2.21 ± 3.00 | 4.78 ± 4.58 | <0.001 |

* Cumulative dose (mg of prednisolone or its equivalent) during the 1-year interval between BMD tests.
* P value calculated with Fisher’s exact test.
* P value calculated with chi-square test.

BMD: body mass index; RF: rheumatoid factor; anti-CCP Ab: anti-cyclic citrullinated peptide antibody; csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs; MTX: methotrexate; HCQ: hydroxychloroquine; SSZ: sulfasalazine; LEF: leflunomide; TAC: tacrolimus; bDMARDs: biologic disease-modifying anti-rheumatic drugs; TNFi: tumor necrosis factor inhibitor; DAS28-ESR: disease activity score 28-erythrocyte sedimentation rate; BMD: bone mineral density.
FIGURE 1 | One year % change in (A), lumbar spine BMD and (B), femoral neck BMD according to the dose of vitamin D supplementation. The whiskers represent the 10–90 percentile range, and the black dots represent values outside the 10–90 percentile range. *p < 0.05, **p < 0.001. BMD, bone mineral density.

TABLE 2 | Linear regression model estimates of the effect of vitamin D supplementation based on 1-year % changes in BMD.

|          | Univariable analysis | Multivariable analysis* |
|----------|----------------------|-------------------------|
|          | β (95% CI)            | P                       | β (95% CI)            | P      |
| LUMBAR SPINE |                      |                         |                        |        |
| 0 IU/day  | 0 (ref.)              | 0 (ref.)                | 0.047                  | 0.007  |
| 400 IU/day| 3.18 (0.87–5.49)      | 0.007                   | 2.51 (0.04–4.99)       | 0.047  |
| 800 IU/day| 4.46 (2.82–6.10)      | <0.001                  | 2.90 (0.47–5.33)       | 0.020  |
| ≥1,000 IU/day| 6.71 (4.61–8.82)    | <0.001                  | 6.01 (3.71–8.32)       | <0.001 |
| FEMORAL NECK  |                      |                         |                        |        |
| 0 IU/day  | 0 (ref.)              | 0 (ref.)                | <0.001                 | <0.001 |
| 400 IU/day| 3.92 (1.99–5.84)      | <0.001                  | 3.86 (1.83–5.94)       | <0.001 |
| 800 IU/day| 4.30 (2.94–5.67)      | <0.001                  | 4.30 (2.25–6.35)       | <0.001 |
| ≥1,000 IU/day| 6.88 (5.12–8.63)   | <0.001                  | 6.79 (4.87–8.71)       | <0.001 |

*Multivariable model adjusted for age, sex, BMI, total glucocorticoid dose prior to the initial BMD test, cumulative glucocorticoid dose between BMD tests, use of csDMARDs and bDMARDs, DAS28-ESR, and type of bisphosphonate.

TABLE 3 | Linear regression model estimates of the difference in 1-year % changes in BMD between the ≥1,000- and 800-IU/day groups.

|          | Univariable analysis | Multivariable analysis* |
|----------|----------------------|-------------------------|
|          | β (95% CI)            | P                       | β (95% CI)            | P      |
| LUMBAR SPINE |                      |                         |                        |        |
| 800 IU/day | 0 (ref.)              | 0 (ref.)                | 3.11 (0.86–5.37)       | 0.007  |
| ≥1,000 IU/day| 2.25 (0.21–4.30)    | 0.031                   | 2.50 (0.63–4.36)       | 0.009  |
| FEMORAL NECK  |                      |                         |                        |        |
| 800 IU/day | 0 (ref.)              | 0 (ref.)                | <0.001                 | <0.001 |
| ≥1,000 IU/day| 2.57 (0.87–4.27)    | <0.001                  | 2.50 (0.63–4.36)       | 0.009  |

*Multivariable model adjusted for age, sex, BMI, total glucocorticoid dose prior to the initial BMD test, cumulative glucocorticoid dose between BMD tests, use of csDMARDs and bDMARDs, DAS28-ESR, and type of bisphosphonate.

which may also explain the higher magnitude of 1-year % change in BMD in our study.

In vitamin D deficiency, 1, 25-(OH)-vitamin D interacts with receptors in the osteoblasts, thereby leading to the increased formation of osteoclasts (20). The mature osteoclast then releases enzymes to break down the bone matrix, ultimately releasing calcium and other minerals into the circulation (21). Therefore, vitamin D supplementation is important in the treatment of osteoporosis (22). The higher increase in BMD observed in patients receiving a vitamin D supplementation dose higher than the dose (600–800 IU/day) recommended in the general osteoporosis patients might be attributable to the fact that patients with RA have a higher prevalence and more severe degree of vitamin D deficiency than the general population (9, 10, 23).

A previous study has shown that in trials in which a mean 25-(OH)-vitamin D level of 100 nmol/L was achieved, optimal prevention of osteoporotic fracture was observed (22). In studies in which baseline 25-(OH)-vitamin D levels were between 40 and 77 nmol/L, patients achieved a 25-(OH)-vitamin D level of 100
nmol/L with the supplementation of vitamin D at a dose of 700–800 IU/day (18, 24), whereas in studies in which the baseline levels were as low as 21–26 nmol/L, patients failed to achieve a 25-(OH)-vitamin D level of 100 nmol/L with the supplementation of vitamin D at a dose of 800 IU/day (19, 25). These findings support the notion that patients with vitamin D deficiency, such as those with RA, may benefit from a vitamin D supplementation dose higher than 800 IU/day to improve BMD. Moreover, considering that vitamin D deficiency is inversely associated with the disease activity of RA (9, 10), vitamin D supplementation at a higher dose might be beneficial in improving not only BMD but also the disease activity of RA. However, as vitamin D intoxication can result in the mobilization of skeletal calcium, leading to bone demineralization (26), increasing the dose of vitamin D supplementation indefinitely cannot be advocated. The suggested upper limit of vitamin D intake is 4,000 IU/day (6).

Treatment of RA may affect BMD in RA patients with osteoporosis (27–29). Use of glucocorticoid is associated with reduction in BMD (27), while use of tumor necrosis factor inhibitors is associated with increase in BMD in RA patients (28). Similarly, in our multivariable analysis, use of tumor necrosis factor inhibitor was associated with a higher increase of 1-year % change in lumbar spine BMD (β = 2.89 [95% CI: 0.93–4.85], p = 0.004), while the cumulative glucocorticoid dose between BMD tests was associated with a lower increase of 1-year % change in femoral neck BMD (β = −0.001 [95% CI: −0.002 to −0.001], p = 0.001) (Supplementary Table 1). In regard to csDMARDs, leflunomide may possibly be associated with an increase in lumbar spine BMD (29). In the present study, use of leflunomide had a positive effect on lumbar spine BMD (β = 1.02) as well, although it failed to reach statistical significance (95% CI: −1.01 to 3.04, p = 0.324) (Supplementary Table 1).

We presume that this is because the outcome parameter was used as a continuous variable in the present study whereas in the previous study the outcome parameter was used as a categorical variable (29).

The present study had some limitations. First, this was a retrospective study, and data about the lifestyle habits of each patient, such as diet, alcohol intake, and exercise, were not available. The risk of confounding caused by these undetermined variables might exist. Further, due to the nonrandomized retrospective group allocation, possibility of selection bias cannot be excluded. Second, data about vitamin D levels were missing. Owing to the lack of these data, the proportion of patients with vitamin D deficiency at baseline was not identified and whether patients who are not deficient in vitamin D also will benefit from a higher dose of vitamin D supplementation was not evaluated. Third, although we found that ≥1,000 IU/day of vitamin D supplementation was associated with a higher increase in 1-year % change in BMD than 800 IU/day of supplementation, we were unable to determine the optimal dose of vitamin D supplementation because only a small fraction of patients received a dose of more than 1,000 IU/day. Further study investigating the optimal dose of supplementation of vitamin D, probably over 1,000 IU/day, is needed. Fourth, although we adjusted for the type of bisphosphonate in the multivariable analysis, bias which results from the higher use of risedronate in the 0-IU/day group and higher use of alendronate in the 400, 800, and ≥1,000 IU/day group cannot be fully adjusted.

In conclusion, we observed a significantly higher increase in lumbar spine and femoral neck BMD in 1 year in RA patients with osteoporosis receiving vitamin D supplementation compared with those who did not. The increase in BMD was the highest in patients who received a vitamin D supplementation dose of ≥1,000 IU/day. Our finding suggests that RA patients with osteoporosis who are receiving bisphosphonate may benefit more when a higher dose of vitamin D is supplemented than patients with osteoporosis in the general population.

DATA AVAILABILITY STATEMENT
All datasets presented in this study are included in the article/Supplementary Material.

ETHICS STATEMENT
This study was approved by the Institutional Review Board (IRB) of Gangnam Severance Hospital (IRB No: 3-2020-0043) and Asan Medical Center in Seoul, South Korea (IRB No: 2018-0090). Requirement of informed consent was waived because of the retrospective nature of the study. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS
M-CP and Y-GK conceived the study. OK, M-CP, and Y-GK designed the study. OK, M-CP, and Y-GK participated in the acquisition of data, data analyses, and data interpretation. OK, M-CP, and Y-GK wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING
This study was supported by a faculty research grant from Yonsei University College of Medicine to OK (6-2019-0111) and a grant from the National Research Foundation of Korea to Y-GK (NRF-2019R1F1A1059736).

ACKNOWLEDGMENTS
We thank the Biostatistics Collaboration Unit, Yonsei University College of Medicine, for the statistical support.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2020.00443/full#supplementary-material
REFERENCES

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. (2016) 388:2023–38. doi: 10.1016/S0140-6736(16)30173-8

2. Haugberg G, Uhlig T, Falch JÅ, Halse JL, Kven TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 391 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. (2000) 43:522–30. doi: 10.1002/1529-0131(200003)43:3&lt;522::AID-ANR7&gt;3.0.CO;2-Y

3. Kroger H, Honkanen R, Saarikoski S, Alhava E. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study. Ann Rheum Dis. (1994) 53:18–23. doi: 10.1136/ard.53.1.18

4. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. (2017) 69:1521–37. doi: 10.1002/art.40137

5. Park SY, Gong HS, Kim KM, Kim D, Kim H, Jeon CH, et al. Korean Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. J Rheumatic Dis. (2011) 25:263–95. doi: 10.4078/jrd.2018.25.4.263

6. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. (2011) 96:53–8. doi: 10.1067/j.cjem.2011.01.004

7. Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med. (2017) 167:Itc17–32. doi:10.7326/ITC201708010

8. Lips P, van Schoor NM. The effect of vitamin D on bone and osteoporosis. Best Pract Res Clin Endocrinol Metab. (2011) 25:585–91. doi:10.1016/j.beem.2011.05.002

9. Kerr GS, Sabahi I, Richards JS, Caplan L, Cannon GW, Reimold A, et al. Prevalence of vitamin D insufficiency/deficiency in rheumatoid arthritis and associations with disease severity and activity. J Rheumatol. (2011) 38:33–9. doi:10.3899/jrheum.100516

10. Lee YH, Bae SC. Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: a meta-analysis. Clin Exp Rheumatol. (2016) 34:827–33.

11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. (2010) 62:2569–81. doi:10.1002/art.27584

12. Carey JJ, Buehling B. Current imaging techniques in osteoporosis. Clin Exp Rheumatol. (2018) 36(Suppl 114):115–26.

13. Hui SL, Gao S, Zhou XH, Johnston CC, Lu Y, Gluer CC, et al. Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res. (1997) 12:1463–70. doi:10.1359/jbmr.1997.12.9.1463

14. Yoo K, Cho J, Ly S. Vitamin D intake and serum 25-hydroxyvitamin D levels in Korean adults: analysis of the 2009 Korea National Health and Nutrition Examination Survey. (KNHANES IV-3) Using a Newly Established Vitamin D Database. Nutrients. (2016) 8:6610. doi:10.3390/nu8106010

15. Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab. (2008) 93:3430–5. doi: 10.1210/jc.2008-0284

16. Lee Y-K, Choi M-K, Hyun T, Lyu E-S, Park H, Ro H-K, et al. Analysis of dietary calcium and phosphorus intakes and contribution rates of major dish groups according to gender, age, and region in Korea. Korean J Community Nutr. (2020) 25:32–47. doi:10.5720/kjcn.2020.25.1.32

17. Ooms ME, Roos JC, Bezemer PD, van der Vich WJ, Bouter LM, Lips P. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab. (1995) 80:1052–8. doi: 10.1210/jcem.80.4.7714065

18. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. (1997) 337:670–6. doi:10.1056/NEJM199709043371003

19. Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, et al. Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalys II study. Osteoporos Int. (2002) 13:257–64. doi: 10.1007/s001980200023

20. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. (2004) 79:362–71. doi:10.1093/ajcn/79.3.362

21. Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South Med J. (2005) 98:1024–7. doi: 10.1097/01.SMJ.0000140865.32054.DB

22. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. Jama. (2005) 293:2257–64. doi:10.1001/jama.293.18.2257

23. Kostoglou-Athanassiou I, Athanassiou P, Lyraki A, Raftakis I, Antoniadis C. Vitamin D and rheumatoid arthritis. Ther Adv Endocrinol Metab. (2012) 3:181–7. doi:10.7326/17584

24. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ. (1994) 308:1081–2. doi:10.1136/bmj.308.6936.1081

25. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res. (2000) 15:1113–8. doi:10.1359/bmr.2000.15.6.1113

26. Adams JS, Lee G. Gains in bone mineral density with resolution of vitamin D intoxication. Ann Intern Med. (1997) 127:203–6. doi:10.7326/0003-4819-127-3-199708010-00004

27. Kroot EJ, Nieuwenhuizen MG, de Waal Malefijt MC, van Riel PL, Pasker-de Jong PC, Laan RF. Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum. (2001) 44:1254–60. doi: 10.1002/1529-0131(200106)44:6&lt;1254::AID-ART216&gt;3.0.CO;2-G

28. Krieckaert CL, Nurmohamed MT, Wolbink G, Lems WF. Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology. (2013) 52:547–53. doi:10.1093/rheumatology/kes320

29. Kwon OC, Oh JS, Hong S, Lee CK, Yoo B, Kim YG. Conventional synthetic disease-modifying antirheumatic drugs and bone mineral density in rheumatoid arthritis patients with osteoporosis: possible beneficial effect of leflunomide. Clin Exp Rheumatol. (2019) 37:813–9.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.